Platinum Industries Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y18rl47k2fx9tud15nj5ytwq.pdf

Key Takeaways


Growth Engine: Egypt Plant

The Egypt facility is the single most consequential initiative for both revenue scale and margin recovery. It manufactures lead-based commodities (lead stabilizers, metallic stearates) and CPVC compounds, with construction completing by end of May, pre-commissioning in June, and commercial production targeted for 1st September, though the exchange filing conservatively points to December for 100% plant running.

Krishna Rana: "Egypt holds around Multi Free Trade Agreements (FTA)... almost 130 countries can import from Egypt duty-free."

India Capacity & Product Mix

The Palghar expansion adds 60,000 MT, expected to be optimally utilised by March/April, taking total India revenue potential to ~₹1,400 crores (₹700–₹750 crores from PVC, ~₹600 crores from CPVC) over three to four years.

Krishna Rana: "So this is the area where we have entered and supplying additives and not the entire compound."

Pharma & Oleo: The Optionality Bets

Two early-stage ventures sit outside current revenue but carry meaningful medium-term optionality. Neither has committed capex yet; both follow an asset-light, prove-it-first approach.


Margins: The Reset and the Recovery Path

EBITDA margins have structurally reset from 23% in FY23–FY24 to 15% currently, a function of product mix rather than operational deterioration. The recovery story rests on three levers: CPVC raw material optimisation, Egypt's structurally higher margins, and operating leverage as new capacity fills.


Capital Allocation & Promoter Moves

Krishna Rana: "We had sold somewhere around 5,30,000 shares in the market because there were some personal loans which I had to get rid of."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthMore than 40% growthFY27
Revenue CAGR35% CAGRFY26 to FY29
Egypt commercial productionConstruction complete end-May, pre-commissioning June, production start 1st September; 100% plant running by December (exchange filing)September–December 2026
Calcium zinc linesFull-scale commercial productionFrom April 2026
Palghar capacity utilisation60,000 MT facility optimally utilisedBy March/April 2026
Egypt revenue₹250–₹300 croresOver 3 years
Egypt EBITDA margin12%–13% initially, rising to 15%–16%After first 2–3 years
India EBITDA margin15%–17% maintainableOngoing
Oleo capex₹150–₹200 crores for 40,000 tonnes capacityAfter one year of seed marketing
Pharma capexOwn manufacturing investmentPost two to three years of asset-light market entry
Promoter stakeNo further sale plannedShort run

Key Metrics

MetricQ3 FY26
Standalone revenue₹102.62 cr, +31% YoY and +6% QoQ
Consolidated revenue₹104.67 cr, +12% YoY
9M standalone revenue₹302.38 cr, +25% YoY
9M consolidated revenue₹318.42 cr, +7.7% YoY
Gross margin~31%, vs 32.6% in Q3 FY25; higher CPVC mix
EBITDA₹16.25 cr, margin 15.8%
9M EBITDA₹44.11 cr, margin 14.6%
Profit before tax₹17.54 cr, +15% YoY
Profit after tax₹12.93 cr, +18% YoY and +6.5% QoQ
EPS₹2.35
9M PAT₹37.58 cr
CPVC contribution margin~17% in Q3, up from ~12% in H1 and 7% last year
Lead-free products contribution margin30%–35%
Lead products contribution margin (India)18%
Palghar CPVC plant utilisation60%–65% of 12,000 tonnes capacity
Unit 1 flakes capacity utilisation95%
Powder capacity utilisation20%–30%, up from 10% previously
Promoter stake change~1% reduction, 5,30,000 shares sold for personal loan repayment
FY27 revenue growth target>40% (ex-pharma)
FY26–FY29 revenue CAGR target35% (ex-pharma)
Egypt plant commercial production startSeptember 2026 target, with December 2026 final outlook
Egypt revenue potential (3 years)₹250–300 cr, ~50% utilisation of ₹600 cr total capacity
Egypt lead products contribution margin23%–24%
Egypt lead products EBITDA margin (initial)12%–13%, expected to rise to 15%–16%
India factories total revenue potential~₹1,400 cr (PVC: ₹700–750 cr, CPVC: ~₹600 cr) over 3–4 years
Portfolio PAT margin guidance11%–12%
India EBITDA margin maintainable range15%–17% with product mix
Net debt positionNet debt free